Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers.
Similar to our aging society, dogs live longer than before and an increasing number of them die from cancer nowadays. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and chemotherapy. Oral malignant melanoma (OMM), a highly invasive cancer in dogs, is one such example.
In humans, some malignant cancer cells express PD-L1 proteins that bind to their receptor PD-1 on T cells, resulting in the suppression of the T cell’s immune function. Thus, PD-L1/PD-1 interaction is considered an “immune escape mechanism” that cancer cells have. Antibodies that block PD-1/PD-L1 binding have proven effective in inducing anti-tumor immune responses and have been widely used in immunotherapy in the last five years. However, in dogs, no such clinical studies have been reported so far.
Professor Satoru Konnai of Hokkaido University and his collaborators in Japan have developed a chimeric anti-PD-L1 antibody that induces immune responses and therefore tumor regression in dogs with malignant cancers.
The team first revealed that PD-L1 is expressed in the cells of OMM and another type of cancer called undifferentiated sarcoma, confirming that those two cancers are likely targeted by the immunotherapy. They then utilized a rat anti-PD-L1 antibody to develop a rat-dog chimeric antibody which should help avoid rejection by the immune system and allergic reactions when administered to dogs.
In their pilot clinical study, seven dogs with OMM and two dogs with undifferentiated sarcoma were treated with the chimeric antibody every two weeks. One of the OMM dogs showed obvious tumor regression after ten weeks of administration while one dog with undifferentiated sarcoma showed a significant decrease in tumor burden after three weeks. None of them showed adverse effects such as an allergic reaction. Moreover, their data suggested the treatment may have prolonged survival in dogs with OMM after pulmonary metastasis.
“Chimerization of the antibody is now proven as a simple and effective strategy to develop therapeutic antibodies in veterinary medicine. Although further clinical studies are needed, other PD-L1-positive cancers could be targeted by the antibody we have developed,” says Satoru Konnai. “Given the similarity between humans and dogs in cancer biology, our study should provide a beneficial model for human preclinical studies.”
Learn more: New therapeutic antibody for dog cancers
The Latest on: Chimeric antibody
- Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Canceron June 25, 2020 at 9:00 pm
Artiva Biotherapeutics, Inc., announced today the launch of the company with the close of a $78 million Series A financing to advance NK cell therapy.
- Kymab holds off Regeneron in patent fight on home turfon June 24, 2020 at 8:07 am
Chalk one up for antibody maker Kymab. The U.K. Supreme Court invalidated a pair of Regeneron patents around antibody-producing mice, putting to rest a lawsuit Regeneron filed against Kymab seven ...
- KYMAB WINS SUPREME COURT CASE AGAINST REGENERONon June 24, 2020 at 3:11 am
Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, is pleased to announce that the Supreme Court of the United Kingdom has held that all of the ...
- Oncolytic virus-derived type I interferon restricts CAR T cell therapyon June 24, 2020 at 2:34 am
Oncolytic viruses promote an inflammatory response and elicit anti-tumor immunity. Here the authors show, unexpectedly, that the oncolytic virus, VSVIFNβ, induces type I interferon responses that, ...
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Credit Suisse Biotech Management & Board Call Series Conference (Transcript)on June 22, 2020 at 11:27 am
Credit Suisse Biotech Management & Board Call Series Conference June, 22 2020, 08:00 AM ET Company Participant ...
- Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020on June 19, 2020 at 8:45 am
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today presented data from preclinical studies of its hemophilia B gene therapy CB 2679d-GT at the World Federation of Hemophilia Virtual Summit, taking place ...
- Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19on June 17, 2020 at 5:12 am
The 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab are described in a manuscript by De Luca et al 1 entitled, “GM-CSF Blockade with Mavrilimumab in Severe COVID ...
- Worldwide Monoclonal Antibody Partnering Terms and Agreements 2014 - 2020 - ResearchAndMarkets.comon June 17, 2020 at 3:22 am
The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.
- SARS-CoV-2 mutated spike proteins show variations in cell entryon June 16, 2020 at 10:56 pm
A new study by Japanese scientists published on the preprint server bioRxiv* in June 2020 shows that the D614g mutation in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ...
- Zaia Draws on Decades of Innovation in Infectious Disease for Breakthroughs in Gene Therapyon June 16, 2020 at 6:23 pm
Known as a gene therapy pioneer, Zaia has spent almost 40 years at City of Hope, in Duarte, California. He was first drawn by the promise of studying cytomegalovirus. Over the decades, his ...
via Google News and Bing News